搜尋
ESSA Pharma Inc
EPIX添加自選
0.201USD
0.0000.00%
收盤 07/02, 13:00（美東）報價延遲15分鐘
8.93M總市值
虧損本益比TTM
關於 ESSA Pharma Inc 公司
ESSA Pharma Inc. 是一家加拿大臨牀階段製藥公司。該公司專注於開發治療前列腺癌患者的專有療法。其主要候選藥物 Masofaniten（原名 EPI-7386）是一種口服小分子，可抑制雄激素受體 (AR) 的 N 端結構域。Masofaniten 正在開發中，用於與抗雄激素療法聯合治療早期前列腺癌患者。該公司正在完成 Masofaniten 作爲轉移性去勢抵抗性前列腺癌 (mCRPC) 患者的單一療法治療的臨牀開發。
ESSA Pharma Inc簡介
公司代碼EPIX
公司名稱ESSA Pharma Inc
上市日期Feb 22, 2021
CEODr. David Ross Parkinson, M.D.
員工數量35
證券類型Ordinary Share
年結日Feb 22
公司地址999 West Broadway, Suite 720
城市VANCOUVER
上市交易所NASDAQ Capital Market Consolidated
國家Canada
郵編V5Z 1K5
電話17783310962
網址https://www.essapharma.com/
公司代碼EPIX
上市日期Feb 22, 2021
CEODr. David Ross Parkinson, M.D.
ESSA Pharma Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
常見問題
ESSA Pharma Inc的前五大股東是誰？
ESSA Pharma Inc的前五大股東如下：Mr. Jon Adkins
有多少機構持有ESSA Pharma Inc(EPIX)的股份？
截至2025Q3，共有79家機構持有ESSA Pharma Inc的股份，合計持有的股份價值約為34.87M，占公司總股份的73.70% 。與2025Q2相比，機構持股有所增加，增幅為-13442442.00。